Lake Street analyst Chad Messer lowered the firm’s price target on Immunome (IMNM) to $30 from $32 and keeps a Buy rating on the shares. Strategic execution remains on track, while a “significantly bolstered balance sheet” extends the company’s projected cash runway into 2028, the analyst tells investors in a Q4 recap.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome price target raised to $36 from $33 at Craig-Hallum
- Immunome price target lowered to $30 from $33 at Stephens
- Immunome price target raised to $39 from $35 at JPMorgan
- Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
- Immunome reports FY25 EPS ($2.43), consensus ($2.21)